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Abstract
Relaxin is a peptide related to pregnancy that induces nitric oxide-related and gelatinase-
related effects, allowing vasodilation and pregnancy-related adjustments permitting parturi-
tion to occur. Relaxin controls the hemodynamic and renovascular adaptive changes that
occur during pregnancy. Interest has evolved regarding relaxin and a therapeutic principle
in preeclampsia and heart failure. Preeclampsia is a pregnancy disorder, featuring hyper-
tension, proteinuria and placental anomalies. We investigated relaxin in an established
transgenic rat model of preeclampsia, where the phenotype is induced by angiotensin
(Ang)-II production in mid pregnancy. We gave recombinant relaxin to preeclamtic rats at
day 9 of gestation. Hypertension and proteinuria was not ameliorated after relaxin adminis-
tration. Intrauterine growth retardation of the fetus was unaltered by relaxin. Heart-rate
responses and relaxin levels documented drug effects. In this Ang-II-based model of pre-
eclampsia, we could not show a salubrious effect on preeclampsia.
Introduction
Preeclampsia is one of the leading causes of maternal and fetal mortality and morbidity, com-
plicating 3–8% of pregnancies.[1] The disease is characterized by new onset of maternal hyper-
tension after 20th week of gestation and proteinuria or in association with thrombocytopenia,
impaired liver function, the new development of renal insufficiency, pulmonary edema, or
new-onset of cerebral or visual disturbances.[2] Preeclampsia originates in the placenta, but
the underlying etiology is complex and probably heterogeneous in origin.[1]
Although the molecular mechanisms leading to preeclampsia remain largely unknown, the
disturbed placental function in early pregnancy is a major contributor in the leading hypothe-
ses. Impaired endovascular trophoblast invasion and vascular remodeling of the spiral artery is
an early, but not necessarily the primary, pathology involved in preeclampsia.[3] The clinical
syndrome “preeclampsia” might result from imbalance between factors produced by the pla-
centa in response to abnormal placentation and maternal adaptation to them leading to
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endothelial dysfunction and increased vascular reactivity.[4] At this stage profound systemic
vasoconstriction is a prominent feature of preeclampsia with hypertension, renal dysfunction,
and multiple organ failure. Reduced blood flow to the placenta inducing soluble, vasoactive fac-
tors, such as sFlt1 might be the underlying mechanism.[5]
The various functions of relaxin suggest that administration of this protein to women with
preeclampsia may be an interesting therapeutic approach.[6] Relaxin is a protein hormone of
about 6000 Da first described in 1926. [7] Relaxin regulates maternal adaptations to pregnancy
with several effects potentially relevant to the treatment of acute heart failure, including
increased arterial compliance, cardiac output, and renal blood flow.[8] The effects of relaxin
include the production of nitric oxide, inhibition of the renin-angiotensin and endothelin sys-
tem, production of VEGF, and induction of gelatinases, such as matrix-metalloproteinases.
These effects lead to systemic and renal vasodilation, increased arterial compliance, and other
vascular changes which have been reviewed in detail.[9] The molecular mechanisms of relaxin
vasodilation depend on the duration of hormone exposure. There are rapid and sustained vaso-
dilatory responses.[10] Conrad et al indicated that the vasodilatory responses of relaxin are
transduced by a specific G protein-coupled receptor, RXFP and are mediated by Gαi/o protein
coupling to phosphatidylinositol 3-kinase/Akt (protein kinase B)–dependent phosphorylation
and activation of endothelial nitric oxide synthase (NOS).[10]
We tested the effects of relaxin in a transgenic rat model of preeclampsia, which is generated
by mating female rats transgenic for human angiotensinogen with rats transgenic for human
renin. [11, 12] Dams exhibit an increase in blood pressure from 100/80 mm Hg to 180/140 mm
Hg and develop proteinuria at the end of pregnancy. The model is associated with altered pla-
centation, modified resistance index, and endothelial dysfunction. Although upregulation of
the renin-angiontensin system is the underlaying mechanism in this model, a disturbed prosta-
cyclin:thromboxane ratio is an important mediator of the increased vasoconstriction and
abnormal vasocreactivity.[13] The uteroplacental units present a pathological endovascular
and interstitial trophoblast invasion and display an altered vascular remodeling.[14–16].
Methods
Female Sprague-Dawley (SD) rats harboring the human angiotensinogen gene [TGR(hAogen)
L1623] were mated with male SD rats bearing the human renin gene [TGR(hRen)L10J], after
the implantation of radiotelemetry pressure transducers (TA11PA-C20, Data Sciences Interna-
tional, La Jolla, Calif) as described before.[17, 18]. The radiotelemetry pressure transducers
were implanted in the abdominal cavity of the rat under isoflurane anesthesia (isoflurane dose
of 1.6% in 400 ml/min air flow), with the transducer connected capillary tubing anchored in
the lumen of the abdominal aorta. Before the implantation the zero offset was measured and
the unit was soaked in 0.9% NaCl. Before surgery, the animal receives an analgesic dose of car-
profen (Rimadyl1, 5mg/kg, subcutane). Xylocaine 2% Jelly was used as local surface anesthe-
sia after surgery. Animals were allowed to recover for 10 days. We were aware that female
hAogen rats mated with male hRen rats would develop the preeclamptic syndrome.[17, 18]
The observation of plug in the vagina is indicating the day 1 of pregnancy. On gestational day
9, hAogen transgenic dams were randomly assigned to 2 experimental groups: vehicle (20 mM
sodium acetate, pH 5.0, n = 5) or relaxin (n = 5), at a dose of 2 μg/h of relaxin by subcutaneous
osmotic minipump (Alzet, Typ 2002) until day 21 of gestation. Subcutaneous implantation of
osmotic pumps was done under isoflurane anesthesia (isoflurane dose of 1.9% in 400 ml/min
air flow). Twenty-four-hour urine samples were collected in metabolic cages at day 17/18 of
gestation. Rats were killed at day 21 of gestation by decapitation after prior anesthesia with iso-
flurane. The fetuses and organs were removed and weighed. Serum and plasma samples were
Relaxin and Preeclampsia
PLOS ONE | DOI:10.1371/journal.pone.0150743 March 10, 2016 2 / 11
Competing Interests: The work was funded by grant
in aid by Novartis. Ralf Dechend is employed and
affiliated with the Charité and the HELIOS Clinic.
There are no financial or non-financial, professional,
or personal competing interests and assure financial
disclosure for the entire manuscript. The affiliation to
HELIOS has no influence on employment,
consultancy, patents, products in development, or
marketed products for this manuscript. The funders
had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript. This does not alter the authors'
adherence to all PLOS ONE policies on sharing data
and materials, as detailed online in PLOS ONE guide
for authors.
collected. Sprague-Dawley females were mated with Sprague-Dawley males as controls, namely
pregnant Sprague-Dawley (SD). SD rats were killed at day 21 of gestation. Serum and plasma
samples, as well as uteroplacental units were collected. Local authorities approved the studies
(State Office of Health and Social Affairs Berlin; permit number: G0015/13) and all procedures
were done according to guidelines from the American Physiological Society. All surgery was
performed under isoflurane anesthesia, and all efforts were made to minimize suffering.
Human recombinant relaxin was kindly provided by Novartis, Switzerland and has been
shown previously to be bioactive in rodents.[19]
Urinary rat albumin was measured with a commercially available ELISA (CellTrend, Ger-
many). Serum concentration of human (Immundiagnostik, Germany) and rat relaxin (MyBio-
Source, USA) was also measured with a commercially available ELISA. Serum cystatin C was
measured with a commercially available ELISA (BioVendor, Germany) and serum creatinine
were determined by an automated clinical method.
Analysis of renal gene expression: Total mRNA was isolated with TRIZOL followed by the
Qiagen protocol, and TaqMan reverse-transcription polymerase chain reaction (RT-PCR) was
performed as recommended by the manufacturer. Quantitative analysis of target mRNA expres-
sion was performed with real-time PCR using the relative standard curve method. Real-time
PCR was detected on ABI 7500 Fast Sequence Detection System (Applied Biosystems) and ana-
lyzed by 7500 Fast System Software (Applied Biosystems). Primers and probes were designed
with PrimerExpress 3.0 (Applied Biosystems) and synthesized by Biotez (Germany). The expres-
sion levels of the target gene NGAL in the kidney was normalized to 18S as the endogenous con-
trol. The following primers were used for reverse transcriptase, PCR amplification and detection:
NGAL: CAGGGCAGGTGGTTCGTT (forward), AGCGGCTTTGTCTTTCTTTCTG (reverse),
CGGCCTGGCAGCGAATGC (probe). 18S: ACATCCAAGGAAGGCAGCAG (forward), TTT
TCGTCACTACCTCCCCG (reverse), CGCGCAAATTACCCACT CCCGAC (probe).
Angiotensin metabolites levels in the serum were measured by Attoquant Diagnostics
GmbH (Vienna, Austria). Using mass spectrometry they investigated Ang II levels and the fol-
lowing Ang metabolites:, Ang 1–10 (Ang I), Ang 1–8 (Ang II), Ang 1–7 (MAS receptor ago-
nist), Ang 2–8 (Ang III), and Ang 3–8 (Ang IV) as well as Ang 1–5, Ang 1–9, Ang 2–7, Ang
2–10 and Ang 3–7. Samples were spiked with 100 pg/ml stable-isotope-labeled internal stan-
dards and subjected to solid-phase extraction using Sep-Pak cartridges (Waters) according to
manufacturer’s protocol. Following elution and solvent evaporation, samples were reconsti-
tuted in 50 μl 50% acetonitrile/0.1% formic acid and subjected to LC-MS/MS analysis using a
reversed-phase analytical column (Luna C18, Phenomenex) using a gradient ranging from
10% acetonitrile/0.1% formic acid to 70% acetonitrile/0.1% formic acid in 9 minutes. The elu-
ate was analyzed in line with a QTRAP-4000 mass spectrometer (AB Sciex) operated in the
MRMmode using dwell times of 25 msec at a cone voltage of 4000 volts and a source tempera-
ture of 300°C. For each peptide and corresponding internal standards, two different mass tran-
sitions were measured. Ang II peptide concentrations were calculated by relating endogenous
peptide signals to internal standard signals.
Rat uteroplacental units were fixed in buffer according to Beckstead J.H.[20] truncated from
two lateral placental parts and embedded in paraffin. Paraffin embedded tissue was cut into
3 μm histological sections at the mid sagittal plane. Tissue sections were deparaffinized, rinsed
in distilled water, and dehydrated twice in ethanol 70%. Masson Trichrome staining were per-
formed using standard protocols. Image acquisition was performed using a slide scanner
(Mirax Midi Slide Scanner) For the interpretation of vascular remodeling of spiral arteries the
outer diameter (OD) and luminal diameter (LD) of each vessel were measured at the point of
the largest OD using Pannoramic Viewer (3D Histech). The ratio of LD:OD was used to com-
pare the proportionate vessel wall thickness of the spiral arteries in the mesometrial triangle.
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All data are presented as means ± SEM. Group differences were analyzed by t test, Mann–
Whitney U test, or ANOVA with Bonferroni post hoc test, as appropriate. A value of p< 0.05
was considered statistically significant.
Results
In pregnant rats naturally occurring rat relaxin serum levels were increased during pregnancy
nevertheless no differences in relaxin serum concentration between nontransgenic Sprague-
Dawley (SD) rats and transgenic preeclamptic rats were observed (Fig 1A). Telemetric mea-
sured heart rate values of vehicle and relaxin preeclamptic rats are shown in Fig 1B. Relaxin
treated preeclamptic rats developed significantly increased heart rates directly after the admin-
istration at gestational day 9 (355.0 ± 4.4 bmp vehicle vs. 403.8 ± 11.0 bpm relaxin, p = 0.0033)
and had sustained until day 15. Treatment with recombinant human relaxin led to serum con-
centrations that were 500 pg/ml or so at gestational day 21. We detected no human relaxin in
vehicle-treated preeclamptic rats (Fig 1C). The continuously infused human relaxin by osmotic
minipump at 2 μg/h for 12 days led only to a slight elevation of 4.9% of the endogenous relaxin
amount (Fig 1D).
Telemetric measured mean arterial blood pressure (MAP) values of vehicle and relaxin
treated hAogen transgenic dams mated with a male hRen transgenic rats are shown in Fig 2A.
Vehicle treated preeclamptic rats developed hypertension abruptly at gestational day 13 and
had sustained hypertension until shortly before delivery, when blood pressure decreased
slightly. Relaxin treatment begun even before hypertension developed on gestational day 9 and
did not prevent the increase in blood pressure in the last third of pregnancy (MAP on day16 of
gestation: 151.1 ± 2.2 mmHg vehicle vs. 156.6 ± 1.3 mmHg relaxin). Mean arterial blood pres-
sure area under the curve was calculated and yielded no differences between vehicle and relaxin
treated rats (Fig 2B).
Albuminuria (Fig 3A) that occurred in vehicle treated preeclamptic rats in the third trimes-
ter was not ameliorated by relaxin (14.6 ± 5.5 mg/d vehicle vs. 20.8 ± 3.8 mg/d relaxin). Fur-
thermore, relaxin administration in preeclamtic rats had no influence on serum creatinine (Fig
3B, 21.0 ± 1.4 μmol/l vehicle vs. 22.2 ± 1.6 μmol/l relaxin) and cystatin C (Fig 3C, 844.8 ± 68.5
ng/ml vehicle vs. 732.2 ± 36,0 ng/ml relaxin) concentration compared to vehicle group. More-
over there was no influence on renal NGAL mRNA expression by the administration of relaxin
(Fig 3D). To explore the influence of relaxin on renin-angiotensin system (RAS) we measured
Fig 1. Effect of relaxin on heart rate and relaxin serum concentration. (A) Rat relaxin was increased during pregnancy in transgenic and non-transgenic
control rats. (B) Telemetrically measured heart rates. Relaxin treatment leads to an immediately increase in heart rate compared to vehicle treated rats. The
arrow with plug indicates the observation of plug in the vagina, indicating day 1 of pregnancy. Start of treatment is indicated by the dotted line. (C) Human
recombinant relaxin was present in the relaxin and not detectable (n.d.) in vehicle treated animals. All results are expressed as mean ± SEM of 5 animals per
group, * p<0.05. (D) Illustration of absolute relaxin amount by the addition of endogenous and exogenous relaxin levels (demonstrated in A and C).
doi:10.1371/journal.pone.0150743.g001
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serum angiotensin metabolites mass spectroscopy. We could not detect significantly changes in
the amount of all of them in the circulation between vehicle and relaxin treated rats (Fig 4).
The number of live fetuses was similar between the groups (11.2 ± 1.3 vehicle vs. 9.4 ± 1.9
relaxin). Although relaxin treatment seemed to have a partial deleterious effect on the outcome
of these pregnancies: the percentage of resorptions per pregnant female rat was higher. Fetal
and uteroplacental unit weights are shown in Fig 5. Fetal weights (Fig 5A) were unaffected by
relaxin treatment (3.072 ± 0.062 g vehicle vs. 2.996 ± 0.072 g relaxin). Uteroplacental unit
weights (Fig 5B) were also unchanged in vehicle versus relaxin treated preeclamptic rats
(0.518 ± 0.011 g vehicle vs. 0.537 ± 0.017 g relaxin). To characterize intrauterine growth retar-
dation (IUGR), we investigated the brain to liver ratio in the fetuses (Fig 5C). Relaxin treatment
had no influence on the brain to liver ratio consistent with IUGR (0.795 ± 0.021 vehicle vs.
0.795 ± 0.016 relaxin). Moreover spiral artery remodeling of the uteroplacental unit of pre-
eclamptic rats was not affected by the administration of relaxin. Trichrome staining of
Fig 2. Effect of relaxin on blood pressure. (A) Telemetrically measured mean arterial blood pressures.
Hypertension occurred abruptly at day 13 of gestation and at the end of pregnancy there was some decline in
vehicle treated preeclamtic rat model. Relaxin treatment did not prevent the rise in blood pressure. The arrow
with plug indicates the observation of plug in the vagina, indicating day 1 of pregnancy. Start of treatment is
indicated by the dotted line. (B) Calculated mean arterial blood pressure area under the curve showed no
differences. Results are expressed as mean ± SEM of 5 animals per group.
doi:10.1371/journal.pone.0150743.g002
Fig 3. Effect of relaxin on renal function (A) Albuminuria was present in vehicle treated animals and was
not changed by realxin. (B) Serum creatinine and (C) cystatin C were not altered after administration of
relaxin. (D) The expression of renal NGAL was not different between vehicle and relaxin treated rats. All
results are expressed as mean ± SEM of 5 animals per group.
doi:10.1371/journal.pone.0150743.g003
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uteroplacental units revealed that SD mesometrial triangles had thin-walled spiral arteries
compared to vehicle and relaxin treated PE rats. The vessels in this region of vehicle and relaxin
treated rats showed a significant thickened arterial wall (Fig 6).
Discussion
Relaxin did not ameliorate the preeclamptic phenotype in our transgenic rat model although it
showed biological activity. Relaxin treatment had no influence on blood pressure, urinary albu-
min excretion. Furthermore, no improvement of intra-uterine growth retardation and vascular
remodeling was observed.
Our rodent model of preeclampsia is based on the secretion of active renin from the pla-
centa or the fetus, which interacts with circulating maternal hAGT leading to increased circu-
lating and local angiotensin II. In normal pregnancy relaxin is one of the leading hormones
leading to remarkable maternal cardiovascular adaptation and attenuation to systemic pressor
response to vasoconstrictors, including angiotensin II and norepinephrine [21]. The rationale
to propose relaxin administration to women with preeclampsia is based on the hormone’s
vasodilatory attributes, which subsequently might improve organ perfusion. Different path-
ways modulated by relaxin lead to a potent augmentation of systemic and renal vasodilation by
reducing the myogenic reactivity in small renal arteries [22]. Relaxin can directly act on both
arterial smooth muscle cells as well as on endothelial cells. Increased production of metallopro-
teinases, and the generation of endothelin, which then acts via endothelin receptors to activate
cGMP and NO are important mechanisms [23]. Moreover, there is a rapid relaxin response in
these vessels involving RXFP1 coupling to PI3-kinase and the phosphorylation/activation of
eNOS [19]. Nevertheless relaxin did not reduce the preeclamptic phenotype, leaving the
authors puzzled by the negative results.
However, the Ang II mediated vasoconstriction might be too striking for relaxin to show it
´s positive vasodilating properties and the relaxin dosages archived cannot counteract Ang II
Fig 4. Effect of relaxin on angiotensin metabolites. Serum angiotensin metabolites levels were not
significant different between vehicle and relaxin treated rats. All results are expressed as mean ± SEM (n = 3
vehicle, n = 3 relaxin).
doi:10.1371/journal.pone.0150743.g004
Fig 5. Effect of relaxin on fetal phenotype. Fetal weight (A) Uteroplacental unit weight (B), and brain to liver
weight ratio (C) in vehicle and relaxin treated hAogen TGR dams at gestational day 21. Fetal (A) and
uteroplacental unit (B) weights, as well as brain to liver ratios (C) were similar between vehicle and relaxin
treated preeclamptic rats. All results are expressed as mean ± SEM (n = 51 vehicle, n = 47 relaxin).
doi:10.1371/journal.pone.0150743.g005
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action. The described mechanisms should counteract the detrimental effects of Ang II on the
renal circulatory response to Ang II [24]. But if hypertension is not reduced, the protective
effects of relaxin could also be harmful, leading to progressive loss of autoregulation and
increased pressure injury. In normal pregnant rats without hypertension, Smith et al demon-
strated that renal autoregulation remained intact in pregnant rat although relaxin inhibited
myogenic constriction of renal interlobar arteries [25]. This pathomechanism might be differ-
ent if Ang II is chronically up regulated in pregnant rats as in our model.
Relaxin is able to stimulate several immune cell types, particularly in the endometrium [26].
Piccinni et al showed that relaxin activates resident T cells into Th1-like effector cells produc-
ing IFNγ [27]. The potent modulation of a pro-inflammatory cytokine network by relaxin
might be important for appropriate implantation and placentation [28]. However, the impor-
tance of these mechanisms in a pro-inflammatory surrounding during preeclampsia is not
known and might also be implicated into the negative result we observed.
In rats, circulating relaxin is detectable on gestational days 8 or 9 [29]. Our transgenic pre-
eclamptic rats showed similar circulating relaxin during pregnancy like nontrangenic rats. In
Fig 6. Effect of relaxin on spiral artery remodeling.Representative images of Masson Trichome-stained
uteroplacental unit sections of SD, vehicle and relaxin treated PE rats at gestational day 21. Maternal vessels
in the mesometrial triangle of SD rats (upper left panel) showed thin arterial walls. In contrast, vessels in this
region of vehicle (upper middle panel) and relaxin (upper right panel) treated PE rats a thickened arterial wall.
These differences are summarized as ratios of the inner lumen to-outer diameter ratios (LD/OD) (lower
panel). The outer diameter (OD, red line) and luminal diameter (LD, black line) of each vessel were measured
at the point of the largest OD All results are expressed as mean ± SEM (***p<0.001, SD vs. PE vehicle, SD
vs. PE relaxin; Kruskal-Wallis test with Dunn’s post hoc; n = 354 SD, n = 246 PE vehicle, n = 281 PE relaxin).
doi:10.1371/journal.pone.0150743.g006
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human there are also no differences in serum relaxin levels between women with preeclampsia
and uncomplicated pregnancy [30, 31]. However the mode of action of relaxin suggests benefi-
cial effects in preeclampsia [32], but not many studies have actually investigated relaxin in pre-
eclampsia. No human trial of relaxin has been performed in human preeclampsia. Unemori
et al have presented a rationale and design of a Phase I Safety Study, which has been launched
in the USA [6]. Lafayette et al. observed no significant correlation between serum relaxin con-
centration and renal function in preeclamptic women in the early postpartum period [30]. The
authors conclude that relaxin action may be critical to the development of renal and systemic
vasodilation in the first half of pregnancy, but as the placenta grows, placental vasodilators are
the essential players in order to maintain the vasodilatory state thereafter. Kristiansson et al.
showed low first trimester serum relaxin concentration were associated with increased blood
pressure in the third trimester of pregnancy [33], but relaxin has not been investigated in
respect to risk prediction.
To our knowledge, our study is the first study which investigated relaxin in a pathological
pregnancy condition in rodents. Relaxin had no influence on blood pressure and proteinuria.
A noteworthy limitation to our study is that we measured mean arterial blood pressure and not
renal function as the measured experimental endpoint. We administered relaxin before the
syndrome developed, and we have direct evidence that the peptide was increased substantially.
The threshold dose of recombinant human relaxin in non pregnant rats to observe ameliora-
tion of kidney damage was 0.15 μg/h when given by subcutaneous osmotic minipump [34].
The infusion rate of our relaxin treatment had a 2 μg/h infusion rate, which should be in an
efficient range. Nerveless we only had an elevation of around 5% of the endogenous relaxin
amount. With this approach we observed a signifcant effect on heart rate, indicating that the
approach needs to cardiovascular effects. The physiological increase in relaxin during preg-
nancy might be one reason why the intervention was not successful. To rule the effect of physi-
ological relaxin elimination of relaxin from the circulation of pregnant rats, i.e., ovariectomy
and subsequent maintenance of pregnancy with exogenous estradiol and progesterone before
the start of the intervention would be important [35].
Furthermore we cannot exclude that an earlier start of relaxin therapy has a positive effect
on endorgan damage. From previous studies we know that endovascular and interstitial tro-
phoblast invasion, as well as trophoblast induced vascular remodeling of the spiral arteries are
pathological in our model, which is one mechanism for the severe IUGR observed in our
model [14, 15]. The spiral arteries that supply blood to the placental bed undergo significant
morphological changes in normal pregnancy, including an increase in diameter and a concom-
itant decrease in smooth muscle cells resulted in thin-walled arteries [36]. The effects of relaxin
on trophoblast function and vascular remodeling is sparse [37, 38], however they implicate
that increasing the local and circulating relaxin concentrations will ameliorate the placental
pathology. Relaxin did not improve the induced vascular remodeling of the pathologic spiral
arteries in our model. The pathological placentation starts around day 4–5, whereas we start
relaxin treatment at day 9. Relaxin is produced already very early during pregnancy by the cor-
pus luteum and acts in an autocrine/paracrine fashion to influence granulosa/cumulus cell
function [39]. Whether relaxin has direct effects on the embryo and/or trophoblast during
implantation is not known, though certainly relaxin modulates the receptive endometrium. In
a non-human primate model of early pregnancy relaxin stimulated uteroplacental vasculariza-
tion by increasing number of arterioles in the endometrium [40]. The role of relaxin in physio-
logical pregnancy in humans and rodents is not understood and species-dependent differences
in relaxin biology might also be responsible for the study.
It appears counterintuitive, that the majority of the maternal circulation adaptation is com-
plete at the end of the first trimester, when fetal and placental diameter is still small [41]. The
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cardiovascular changes are apparently preparatory anticipating the rapid growth phase of the
fetus and placenta in the second and third half of gestation, when oxygen and nutrient
demands rise enormously. Thus an earlier treatment with relaxin might be beneficial.
We have shown in earlier studies that anti-inflammatory therapies ameliorate renal and car-
diac endorgan damage in the offspring of the pregnant rats. These rats harbour both human
transgenes and develop massive hypertensive induced endorgan damage within 7–8 weeks,
leading to a 50% mortality. In this model we also tested two different dosages of relaxin [42].
Both dosages tested did not ameliorate the renal and cardiovascular endorgan damage.
Our disappointment in the results has less to do with the science of relaxin but more is in
terms of offering a therapeutic option for our patients. We believe that our data should not dis-
courage investigators from performing such a trial. First, there are hardly such trials. The
“undoable” trial was Magpie, a study to finally document the utility of magnesium sulphate
[43]. Magnesium sulphate is a straightforward therapy accepted for 50 years. Other studies in
preeclamptic women are more controversial and difficult. For instance, the removal of sFlt-1
(and possibly also antibodies directed against the Ang II receptor) showed preliminary encour-
aging results but await further investigation [44].
We could not substantiate the idea that in a rat model of preeclampsia relaxin would ame-
liorate the disease. An alternative approach to test the effect of relaxin would be to perform
ovarectomy and sustain pregnancy by adding the necessary hormons to maintain pregnancy.
With this approach relaxin differences between the groups will be expected to be much higher,
leading to different results. We decided to perform the study as presented since the approach is
closer to the human situation, where relaxin is considered to be applied. Thus, we believe our
data give an additional impetus in a forward direction.
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